Tags

Type your tag names separated by a space and hit enter

The Future of Respiratory Syncytial Virus Disease Prevention and Treatment.
Infect Dis Ther. 2021 Mar; 10(Suppl 1):47-60.ID

Abstract

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children, and older or immunocompromised adults. Although aerosolized ribavirin was licensed for RSV treatment on the basis of data demonstrating a reduced need for supplemental oxygen, ribavirin use is limited because of issues with efficacy, safety, and cost. Currently, the treatment of RSV is primarily supportive. New antiviral treatments for RSV are in the early stages of development, but it will be years until any of these may be licensed by the US Food and Drug Administration (FDA). Palivizumab, an RSV monoclonal antibody [immunoprophylaxis (IP)], has demonstrated effectiveness in disease prevention and is the only licensed IP for RSV disease in specific high-risk pediatric populations. Although its efficacy is well established, some challenges that may interfere with its clinical use include cost, need for monthly injections, and changing policy for use by the American Academy of Pediatrics (AAP). Preventing RSV disease would be possible through RSV vaccine development (e.g., live-attenuated, vector-based subunit, or particle-based). Alternatively, new long-acting monoclonal antibodies have demonstrated promising results in early clinical trials. Despite scientific advances, until new agents become available, palivizumab should continue to be used to reduce RSV disease burden in high-risk patients for whom it is indicated.

Authors+Show Affiliations

Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, USA.Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, USA. mgoldstein@llu.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33656652

Citation

Domachowske, Joseph B., et al. "The Future of Respiratory Syncytial Virus Disease Prevention and Treatment." Infectious Diseases and Therapy, vol. 10, no. Suppl 1, 2021, pp. 47-60.
Domachowske JB, Anderson EJ, Goldstein M. The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infect Dis Ther. 2021;10(Suppl 1):47-60.
Domachowske, J. B., Anderson, E. J., & Goldstein, M. (2021). The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infectious Diseases and Therapy, 10(Suppl 1), 47-60. https://doi.org/10.1007/s40121-020-00383-6
Domachowske JB, Anderson EJ, Goldstein M. The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. Infect Dis Ther. 2021;10(Suppl 1):47-60. PubMed PMID: 33656652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Future of Respiratory Syncytial Virus Disease Prevention and Treatment. AU - Domachowske,Joseph B, AU - Anderson,Evan J, AU - Goldstein,Mitchell, Y1 - 2021/03/03/ PY - 2020/12/08/received PY - 2020/12/09/accepted PY - 2021/3/4/pubmed PY - 2021/3/4/medline PY - 2021/3/3/entrez KW - American Academy of Pediatrics KW - High-risk preterm infants KW - Immunoprophylaxis KW - Monoclonal antibody KW - National Perinatal Association KW - Palivizumab KW - Respiratory syncytial virus KW - Treatment KW - Vaccine SP - 47 EP - 60 JF - Infectious diseases and therapy JO - Infect Dis Ther VL - 10 IS - Suppl 1 N2 - Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children, and older or immunocompromised adults. Although aerosolized ribavirin was licensed for RSV treatment on the basis of data demonstrating a reduced need for supplemental oxygen, ribavirin use is limited because of issues with efficacy, safety, and cost. Currently, the treatment of RSV is primarily supportive. New antiviral treatments for RSV are in the early stages of development, but it will be years until any of these may be licensed by the US Food and Drug Administration (FDA). Palivizumab, an RSV monoclonal antibody [immunoprophylaxis (IP)], has demonstrated effectiveness in disease prevention and is the only licensed IP for RSV disease in specific high-risk pediatric populations. Although its efficacy is well established, some challenges that may interfere with its clinical use include cost, need for monthly injections, and changing policy for use by the American Academy of Pediatrics (AAP). Preventing RSV disease would be possible through RSV vaccine development (e.g., live-attenuated, vector-based subunit, or particle-based). Alternatively, new long-acting monoclonal antibodies have demonstrated promising results in early clinical trials. Despite scientific advances, until new agents become available, palivizumab should continue to be used to reduce RSV disease burden in high-risk patients for whom it is indicated. SN - 2193-8229 UR - https://www.unboundmedicine.com/medline/citation/33656652/The_Future_of_Respiratory_Syncytial_Virus_Disease_Prevention_and_Treatment. L2 - https://dx.doi.org/10.1007/s40121-020-00383-6 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.